Peacehealth Peace Island Medical Center Critical Access Hospital (Medicare Certified) Location: 1117 Spring Street, Friday Harbor, Washington 98250 Ratings:NA Phone: (360) 378-2141 |
News Archive
In 2001, Mount Sinai researchers published a study in Science that showed that a gene, known as KLF6, fails to function properly in at least 50 to 60 percent of all prostate cancers. This was the first single gene shown to be responsible for the majority of cases of this disease, which affects approximately 200,000 men each year.
Shimadzu Scientific Instruments (SSI) announces the release of its new Cannabis Analyzer for Potency. This high performance liquid chromatograph (HPLC) is the first-ever instrument designed specifically for quantitative determination of cannabinoid content. With the Cannabis Analyzer for Potency, operators are now able to produce accurate results with ease, regardless of cannabis testing knowledge or chromatography experience.
Researchers have begun the first definitive, large-scale clinical trial to investigate if a vitamin D supplement helps prevent or delay type 2 diabetes in adults who have prediabetes, who are at high risk for developing type 2. Funded by the National Institutes of Health, the study is taking place at about 20 study sites across the United States.
AA Pharma Inc., a leading distributor of pharmaceuticals in Canada, is pleased to announce the launch of LITHMAX, a sustained release formulation containing 300mg of lithium carbonate. LITHMAX is indicated in the treatment of manic episodes of Bipolar Disorder, as well as the maintenance treatment for individuals with a diagnosis of Bipolar Disorder.
Heptares Therapeutics, the clinical-stage GPCR structure-guided drug discovery and development company and wholly-owned subsidiary of Sosei Group Corporation, is pleased to announce that it has entered into a licensing agreement with AstraZeneca under which AstraZeneca will acquire exclusive global rights to develop, manufacture and commercialise the adenosine A2A receptor antagonist, HTL-1071, a small molecule immuno-oncology candidate, and potential additional A2A receptor-blocking compounds.
› Verified 4 days ago